Literature DB >> 12971027

A review and assessment of potential sources of ethnic differences in drug responsiveness.

Thorir D Bjornsson1, John A Wagner, Stephen R Donahue, Dawn Harper, Aziz Karim, Marlene S Khouri, William R Murphy, Kristin Roman, Dennis Schneck, Daryl S Sonnichsen, Dennis J Stalker, Stephen D Wise, Stuart Dombey, Caroline Loew.   

Abstract

The International Conference on Harmonization (ICH) E5 guidelines were developed to provide a general framework for evaluating the potential impact of ethnic factors on the acceptability of foreign clinical data, with the underlying objective to facilitate global drug development and registration. It is well recognized that all drugs exhibit significant inter-subject variability in pharmacokinetics and pharmacologic response and that such differences vary considerably among individual drugs and depend on a variety of factors. One such potential factor involves ethnicity. The objective of the present work was to perform an extensive review of the world literature on ethnic differences in drug disposition and responsiveness to determine their general significance in relation to drug development and registration. A few examples of suspected ethnic differences in pharmacokinetics or pharmacodynamics were identified. The available literature, however, was found to be heterologous, including a variety of study designs and research methodologies, and most of the publications were on drugs that were approved a long time ago.

Entities:  

Mesh:

Year:  2003        PMID: 12971027     DOI: 10.1177/0091270003256065

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  37 in total

1.  Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.

Authors:  Sujata Vaidyanathan; Joanne Jermany; Chingming Yeh; Marie-Noelle Bizot; Riccardo Camisasca
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

Review 2.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  A population-based analysis of the health experience of African Nova Scotians.

Authors:  Steve Kisely; Mikiko Terashima; Don Langille
Journal:  CMAJ       Date:  2008-09-23       Impact factor: 8.262

4.  Investigation of CYP2D6 Gene Polymorphisms in Turkish Population.

Authors:  Bayram Taskin; Ferda E Percin; Mehmet Ali Ergun
Journal:  Psychopharmacol Bull       Date:  2016-03-01

5.  Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.

Authors:  Mizuki Akahori; Surya Ayalasomayajula; Thomas Langenickel; Parasar Pal; Wei Zhou; Gangadhar Sunkara
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

6.  Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Authors:  Sijie Lu; R A Nand; J S Yang; Gang Chen; A S Gross
Journal:  Eur J Clin Pharmacol       Date:  2017-11-27       Impact factor: 2.953

7.  Support and undermining in interpersonal relationships are associated with symptom improvement in a trial of antidepressant medication.

Authors:  Nataria T Joseph; Hector F Myers; Jonathan R Schettino; Natasha T Olmos; Consuelo Bingham-Mira; Ira M Lesser; Russell E Poland
Journal:  Psychiatry       Date:  2011       Impact factor: 2.458

8.  Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.

Authors:  Yi Han; Surya Ayalasomayajula; Wei Pan; Fan Yang; Yaozong Yuan; Thomas Langenickel; Markus Hinder; Sampath Kalluri; Parasar Pal; Gangadhar Sunkara
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

9.  Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men.

Authors:  Steve Warrington; Shunji Nagakawa; Neil Hounslow
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

10.  Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects.

Authors:  Jasper Dingemanse; Kulasiri A Gunawardena; Paul L M van Giersbergen
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.